Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC.

Cancer Manag Res. 2012;4:253-68. doi: 10.2147/CMAR.S27087. Epub 2012 Aug 14.

2.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
3.

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea.

Kim HJ, Yoon SS, Eom HS, Kim K, Kim JS, Lee JJ, Bang SM, Min CK, Park JS, Lee JH; Korean Multiple Myeloma Working Party.

Blood Res. 2015 Mar;50(1):7-18. doi: 10.5045/br.2015.50.1.7. Epub 2015 Mar 24. Review.

4.

[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].

Roziaková L, Mistrík M, Bátorová A.

Klin Onkol. 2014;27(5):318-25. Review. Czech.

PMID:
25312708
5.

Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.

Mariz JM, Esteves GV.

Curr Opin Oncol. 2012 Jan;24 Suppl 2:S3-11. doi: 10.1097/01.cco.0000410243.84074.dc. Review.

PMID:
22245806
6.

Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.

Delforge M, Michiels A, Doyen C, Kentos A, Van Droogenbroeck J, Offner F, Bries G, Demuynck H, Vekemans MC, Meuleman N, Mineur PO, Ravoet C, Depryck B, Van de Velde A, Pierre P, Wu KL, Schots R.

Acta Clin Belg. 2011 Sep-Oct;66(5):371-5.

PMID:
22145272
7.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M.

Lancet Oncol. 2013 Oct;14(11):1055-66. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.

PMID:
24007748
8.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.

J Clin Oncol. 2009 Dec 1;27(34):5713-9. doi: 10.1200/JCO.2009.22.2679. Epub 2009 Sep 28.

9.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators.

N Engl J Med. 2007 Nov 22;357(21):2123-32. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.

10.

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, Kuriakose ET, Migliaccio-Walle K.

Am Health Drug Benefits. 2015 Jun;8(4):204-15.

11.

Lenalidomide: an update on evidence from clinical trials.

Dimopoulos MA, Terpos E.

Blood Rev. 2010 Nov;24 Suppl 1:S21-6. doi: 10.1016/S0268-960X(10)70005-9.

PMID:
21126633
12.

Spotlight on lenalidomide in relapsed or refractory multiple myeloma.

Scott LJ, Lyseng-Williamson KA.

BioDrugs. 2011 Oct 1;25(5):333-7. doi: 10.2165/11207120-000000000-00000. Review.

PMID:
21942918
13.

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson K.

Core Evid. 2010 Jun 15;4:215-45.

14.

Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):38-43. doi: 10.3816/CLML.2010.n.120.

PMID:
21273172
15.

[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].

Takeda Y, Sakaida E, Nakaseko C.

Nihon Rinsho. 2015 Jan;73(1):130-6. Japanese.

PMID:
25626318
16.

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.

Palumbo A, Dimopoulos M, San Miguel J, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P.

Blood Rev. 2009 Mar;23(2):87-93. doi: 10.1016/j.blre.2008.07.003. Epub 2008 Sep 6. Review.

PMID:
18774632
17.

Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.

Reece D, Imrie K, Stevens A, Smith CA; Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care.

Curr Oncol. 2006 Oct;13(5):160-72.

18.

Lenalidomide: new drug. Myeloma: many questions remain unanswered.

[No authors listed]

Prescrire Int. 2008 Dec;17(98):230-2.

PMID:
19422142
19.

Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist.

McCurdy AR, Lacy MQ.

Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155.

20.

Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

Palumbo A, Mateos MV, Bringhen S, San Miguel JF.

Blood Rev. 2011 Jul;25(4):181-91. doi: 10.1016/j.blre.2011.03.005. Epub 2011 Apr 16. Review.

PMID:
21497966

Supplemental Content

Support Center